ML Bisgaard Group – University of Copenhagen

Forward this page to a friend Resize Print Bookmark and Share

Department of Cellular and Molecular Medicine > Research Groups > ML Bisgaard Group

ML Bisgaard Group

Medical Genetics Program 

Research Interests

Hereditary cancer, genetics of tumor development, genotype-phenotype correlations

Current Project Areas

Determining molecular genetic drivers of hypoxia-induced angiogenesis in tumor development. using renal cell carcinoma and central nervous system hemangioblastoma as tumor models. We aim to gain deeper insight to early tumorgenesis and genes that play a part in promoting tumor growth and cyst development.

von Hippel Lindau disease, we aim to better understand the natural history of this hereditary tumor syndrome, including which factors contribute to the variable clinical phenotype of the disease in order to optimize prophylactic surveillance of the affected families.

Endolymphatic sac tumors of the inner ear (ELSTs): In a clinical study of von Hippel-Lindau patients who are predisposed to develop ELSTs, we aim to evaluate the clinical use of audiometry and imaging of the inner ear in early ELST diagnosis.

Hereditary colorectal cancer: characteristics and prevention

Teaching

Human Genetics for medical students and odontological students

Collaborators

The national von Hippel-Lindau coordination group
International ELST study: Steen Gimsing (Vejle Hospital), Carsten Thomsen (Rigshospitalet), Daniel Aguirre (Madrid University hospital), Sally Watts (Guy’s hospital), Hiroshi Kanno (Yokosaka Hospital), Ashok Pillai (Amrita Institute of Medical Science and Research Centre), and Rachel Giles (University Medical Center Utrecht)
Angiogenesis study: The department of clinical genetics, Odense University hospital
Peloton Therapeutics
CAPP2 study group

Selected publications

  • Binderup MLM, Stendell AS, Galanakis M, Møller HU, Kiilgaard JF, Bisgaard ML. Retinal hemangioblastoma: prevalence, incidence and frequency of underlying von Hippel-Lindau disease. Br J Ophthalmol. 2017 Sep 28.

  • Zetner DB, Bisgaard ML. Familial Colorectal Cancer Type X.  Curr Genomics. 2017 Aug;18(4):341-359.  Review

  • Launbjerg K, Bache I, Galanakis M, Bisgaard ML, Binderup MLM. von Hippel-Lindau development in children and adolescents. Am J Med Genet A. 2017 Sep;173(9):2381-2394.

  • Binderup ML, Galanakis M, Budtz-Jørgensen E, Kosteljanetz M, Luise Bisgaard M. Prevalence, birth incidence, and penetrance of von Hippel-Lindau disease (vHL) in Denmark. Eur J Hum Genet. 2017 Feb;25(3):301-307.

  • Binderup ML, Jensen AM, Budtz-Jørgensen E, Bisgaard ML. Survival and causes of death in patients with von Hippel-Lindau disease. J Med Genet. 2017 Jan;54(1):11-18.

  • Daniela Alosi, Marie Luise Bisgaard, Sophie Nowak Hemmingsen, Lotte Nylandsted Krogh, Hanne Birte Mikkelsen, and Marie Louise Mølgaard Binderup. Management of Gene Variants of Unknown Significance: Analysis Method and Risk Assessment of the VHL Mutation p.P81S (c.241C>T). Current Genomics, 2016 Aug; 18(1): 93 – 103.

  • Binderup ML, Budtz-Jørgensen E, Bisgaard ML. New von Hippel-Lindau manifestations develop at the same or decreased rates in pregnancy. Neurology. 2015 Oct 27;85(17):1500-3.

  • Rudkjøbing LA, Eiberg H, Mikkelsen HB, Binderup ML, Bisgaard ML. The analysis of a large Danish family supports the presence of a susceptibility locus for adenoma and colorectal cancer on chromosome 11q24. Fam Cancer. 2015 Sep;14(3):393-400.

  • Movahedi M, Bishop DT, Macrae F, Mecklin JP, Moeslein G, Olschwang S, Eccles D, Evans DG, Maher ER, Bertario L, Bisgaard ML, Dunlop MG, Ho JW, Hodgson SV, Lindblom A, Lubinski J, Morrison PJ, Murday V, Ramesar RS, Side L, Scott RJ, Thomas HJ, Vasen HF, Burn J, Mathers JC. Obesity, Aspirin, and Risk of Colorectal Cancer in Carriers of Hereditary Colorectal Cancer: A Prospective Investigation in the CAPP2 Study. J Clin Oncol. 2015 Nov 1;33(31):3591-7.

  • Binderup ML, Budtz-Jørgensen E, Bisgaard ML. Risk of new tumors in von Hippel-Lindau patients depends on age and genotype. Genet Med. 2016 Jan;18(1):89-97

  • Binderup, MLM, Gimsing S, Kosteljenetz M, Thomsen C, Bisgaard ML. von Hippel-Lindau disease: Deafness due to a non-MRI-visible endolymphatic sac tumor despite targeted screening. Int J Audiol. 2013 Nov;52(11):771-5

  • Poulsen ML, Gimsing S, Kosteljanetz M, Møller HU, Brandt CA, Thomsen C, Bisgaard ML. von Hippel-Lindau disease: Surveillance strategy for endolymphatic sac tumors. Genet Med. 2011 Dec;13(12):1032-41.

  • Poulsen MLM, Budtz-Jørgensen E, Bisgaard ML. Surveillance in von Hippel-Lindau disease (vHL). Clinical Genetics 2010 Jan;77(1):49-59